In Treatment for Small Cell Lung Cancer

Don't let SCLC survival rates define your journey. Learn why small cell lung cancer prognosis is personal and how new treatments offer hope beyond the statistics.

Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together cancer researchers, oncologists, and advocates to discuss the latest research. Some studies presented at ASCO may eventually change how small cell lung cancer (SCLC) is treated. Others help answer practical questions patients and families have been asking for years. Below is an […]

With small cell lung cancer (SCLC), one complication you’ll likely hear about is chemotherapy-induced myelosuppression. It’s a condition where chemotherapy drugs suppress your bone marrow’s ability to produce healthy blood cells. This matters because blood cells are essential. Red blood cells carry oxygen, white blood cells fight infection, and platelets help blood clot. When chemotherapy […]

If you or a loved one has been diagnosed with extensive-stage small cell lung cancer (SCLC), you may hear about immunotherapy as part of your treatment plan. While chemotherapy has “been in place since the 1990s,” according to Memorial Sloan Kettering Cancer Center’s Dr. Charles Rudin, immunotherapy is changing what longer-term outcomes can look like […]

If you or a loved one has been diagnosed with small cell lung cancer (SCLC), you may hear your care team talk about prophylactic cranial irradiation, or PCI. This preventative treatment may have important implications for a patient’s long-term, overall health outcomes. After being diagnosed with SCLC, it’s important to understand what PCI is and […]

In our recent “Ask the Expert” webinar, we had the privilege of speaking with Dr. Charles Rudin, a leading thoracic oncologist at Memorial Sloan Kettering Cancer Center and a renowned lung cancer expert.  In part two of our discussion, Dr. Rudin answers some of the most common questions patients have about chemotherapy, immunotherapy, recurrence, and […]